- $1.91bn
- $1.49bn
- $255.87m
Schrodinger Inc reports results for the quarter ended June 30 - Earnings Summary
Schrodinger Q2 revenue beats estimates, swings to profit
Brief: Schrodinger Q2 Revenue USD 58.889 Million Vs. IBES Estimate USD 47.2 Million
Brief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Schrodinger Q1 revenue falls 2%, beats analyst estimates
Brief: Schrodinger Q1 Revenue USD 58.587 Million Vs. IBES Estimate USD 48 Million
Brief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Schrödinger Provides Update On Progress Across The Business And Outlines 2026 Strategic Priorities
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software
U.S. RESEARCH ROUNDUP- Alcoa, BlackRock, Evercore
Brief: Schrödinger Reports Inducement Grants Under Nasdaq Listing
Drug developer Schrodinger up after BofA upgrades to 'buy'
Schrödinger Q3 revenue beats estimates on demand for its computational platform
Brief: Schrodinger Q3 Operating Expenses USD 74 Million
Brief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
AI-driven drug discovery picks up as FDA pushes to reduce animal testing
Brief: Schrödinger Reports Inducement Grants
U.S. STOCKS ON THE MOVE-Applied Materials, Charles Schwab, Oracle
U.S. STOCKS ON THE MOVE-Oracle, Kratos, Masimo